Differential metabolism of midazolam in mouse liver and intestine microsomes: A comparison of cytochrome P450 activity and expression

Xenobiotica

Volumn 33, Issue 4, 2003, Pages 365-377

  Perloff, M D ^a   Von Moltke, L L ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; KETOCONAZOLE; MIDAZOLAM;

ANIMAL TISSUE; ARTICLE; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; ENZYME SPECIFICITY; HYDROXYLATION; IMMUNOREACTIVITY; INTESTINE MUCOSA; LIVER METABOLISM; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

ANIMALIA;

EID: 0037870422     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. BENET, L. Z. and CUMMINS, C. L., 2001, The drug efflux-metabolism alliance: biochemical aspects. Advances in Drug Delivery Reviews, 50, S3-S11.
2. COTREAU, M. M., VON MOLTKE, L. L., HARMATZ, J. S. and GREENBLATT, D. J., 2001, Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. Pharmacology, 63, 210-219.
3. DOHERTY, M. M. and CHARMAN, W. N., 2002, The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clinical Pharmacokinetics, 41, 235-253.
4. EMOTO, C., YAMAZAKI, H., IKETAKI, H., YAMASAKI, S., SATOH, T., SHIMIZU, R., SUZUKI, S., SHIMADA, N., NAKAJIMA, M. and YOKOI, T., 2001, Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica, 31, 265-275.
5. EMOTO, C., YAMAZAKI, H., YAMASAKI, S., SHIMADA, N., NAKAJIMA, M. and YOKOI, T., 2000a, Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica, 30, 943-953.
6. EMOTO, C., YAMAZAKI, H., YAMASAKI, S., SHIMADA, N., NAKAJIMA, M. and YOKOI, T., 2000b, Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica, 30, 971-982.
7. GIBBS, M. A., THUMMEL, K. E., SHEN, D. D. and KUNZE, K. L., 1999, Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metabolism and Disposition, 27, 180-187.
8. HONDA, A., SALEN, G., MATSUZAKI, Y., BATTA, A. K., XU, G., LEITERSDORF, E., TINT, G. S., ERICKSON, S. K., TANAKA, N. and SHEFER, S., 2001, Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis. Journal of Biological Chemistry, 276, 34579-34585.
9. HSU, A., GRANNEMAN, G. R. and BERTZ, R. J., 1998, Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical Pharmacokinetics, 35, 275-291.
10. KIM, R. B., WANDEL, C., LEAKE, B., CVETKOVIC, M., FROMM, M. F., DEMPSEY, P. J., RODEN, M. M., BELAS, F., CHAUDHARY, A. K., RODEN, D. M., WOOD, A. J. and WILKINSON, G. R., 1999, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmacology Research, 16, 408-414.
11. KOTEGAWA, T., LAURIJSSENS, B. E., VON MOLTKE, L. L., COTREAU, M. M., PERLOFF, M. D., VENKATAKRISHNAN, K., WARRINGTON, J. S., GRANDA, B. W., HARMATZ, J. S. and GREENBLATT, D. J., In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. Journal of Pharmacology and Experimental Therapeutics, 302, 1228-1237
12. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89-96.
13. MCKINNON, R. A., BURGESS, W. M., HALL, P. M., ROBERTS-THOMSON, S. J., GONZALEZ, F. J. and MCMANUS, M. E., 1995, Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut, 36, 259-267.
14. NEBERT, D. W. and DUY, J. J., 1997, How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Biochemical Pharmacology, 53, 249-254.
15. NEWTON, D. J., WANG, R. W. and LU, A. Y., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
16. ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
17. PAINE, M. F., KHALIGHI, M., FISHER, J. M., SHEN, D. D., KUNZE, K. L., MARSH, C. L., PERKINS, J. D. and THUMMEL, K. E., 1997, Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics, 283, 1552-1562.
18. PERLOFF, M. D., VON MOLTKE, L. L., COTREAU, M. M. and GREENBLATT, D. J., 1999, Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. Biochemical Pharmacology, 57, 1227-1232.
19. PERLOFF, M. D., VON MOLTKE, L. L., COURT, M. H., KOTEGAWA, T., SHADER, R. I. and GREENBLATT, D. J., 2000, Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. Journal of Pharmacology and Experimental Therapeutics, 292, 618-628.
20. QUATTROCHI, L. C. and GUZELIAN, P. S., 2001, CYP3A regulation: from pharmacology to nuclear receptors. Drug Metabolism and Disposition, 29, 615-622.
21. SCHELLENS, J. H., MALINGRE, M. M., KRUIJTZER, C. M., BARDELMEIJER, H. A., VAN TELLINGEN, O., SCHINKEL, A. H. and BEIJNEN, J. H., 2000; Modulation of oral bioavailability of anticancer drugs: from mouse to man. European Journal of Pharmaceutical Sciences, 12, 103-110.
22. SCHMIDER, J., GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S., DUAN, S. X., KARSOV, D. and SHADER, R. I., 1996, Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology, 52, 125-134.
23. SEGEL, I. H., 1975, Enzyme Kinetics (New York: Wiley).
24. SHIMADA, T.; YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
25. THUMMEL, K. E. and WILKINSON, G. R., 1998, In vitro and in vivo drug interactions involving human CYP3A. Annual Reviews of Pharmacology and Toxicology, 38, 389-430.
26. THUMMEL, K. E., O'SHEA, D., PAINE, M. F., SHEN, D. D., KUNZE, K. L., PERKINS, J. D. and WILKINSON, G. R., 1996, Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapy, 59, 491-502.
27. THUMMEL, K. E., SHEN, D. D., PODOLL, T. D., KUNZE, K. L., TRAGER, W. F., HARTWELL; P. S., RAISYS, V. A., MARSH, C. L., MCVICAR, J. P., BARR, D. M., PERKINS, J. D. and CARITHERS, R. L., 1994, Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549-556.
28. TSAO, C. C., FOLEY, J., COULTER, S. J., MARONPOT, R., ZELDIN, D. C. and GOLDSTEIN, J. A., 2000, CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. Molecular Pharmacology, 58, 279-287.
29. TSUNODA, S. M., VELEZ, R. L., VON MOLTKE, L. L. and GREENBLATT, D. J., 1999, Differentiation of intestinal find hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clinical Pharmacology and Therapy, 66, 461-471.
30. VENKATAKRISHNAN, K., VON MOLTKE, L. L. and GREENBLATT, D. J., 2000, Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clinical Pharmacokinetics, 38, 111-180.
31. VENKATAKRISHNAN, K., VON MOLTKE, L. L. and GREENBLATT, D. J., 2001, Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. Journal of Clinical Pharmacology, 41, 1149-1179.
32. VENKATAKRISHNAN, K., VON MOLTKE, L. L., DUAN, S. X., FLEISHAKER, J. C., SHADER, R. I. and GREENBLATT, D. J., 1998, Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. Journal of Pharmaceutics and Pharmacology, 50, 265-274.
33. VON MOLTKE, L. L., GREENBLATT, D. J., GRASSI, J. M., GRANDA, B. W., VENKATAKRISHNAN, K., SCHMIDER, J., HARMATZ, J. S. and SHADER, R. I., 1998, Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Journal of Pharmaceutics and Pharmacology, 50, 997-1004.
34. VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S. and SHADER, R. I., 1993, Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology, 47, 268-276.
35. VON MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., DUAN, S. X., WRIGHT, C. E., HARMATZ, J. S. and SHADER, R. I., 1996, Midazolamihydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. Journal of Clinical Pharmacology, 36, 783-791.
36. WANDEL, C. B., R. H., BOHRER, H., DEVRIES, J. X., HOFMANN, W., WALTER, K., KLEINGEIST, B., NE, S., DING, R., WALTER-SACK, I. and MARTIN, E., 1998, Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metabolism and Disposition, 26, 110-114.
37. WARRINGTON, J. S., POKU, J. W., VON MOLTKE, L. L., SHADER, R. I., HARMATZ, J. S. and GREENBLATT, D. J., 2000, Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 292, 1024-1031.
38. WATKINS, P. B., 1997, The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Advances in Drug Delivery Reviews, 27, 161-170.
39. YANAGIMOTO, T., ITOH, S., SAWADA, M., HASHIMOTO, H. and KAMATAKI, T., 1994, Molecular cloning and functional expression of a mouse cytochrome P-450 (Cyp3a-13): examination of Cyp3a-13 enzyme to activate aflatoxin B1 (AFB1). Biochimica et Biophysica Acta, 1201, 405-410.